NEW YORK, April 24 - Genaissance Pharmaceuticals said Tuesday it had begun enrolling patients for its clinical trials which will aim to correlate haplotypes with individuals’ reactions to particular drugs.
In its initial study, the company plans to enroll about 600 patients at 60 medical centers in the US to correlate patient haplotypes with the affects of cholesterol lowering drugs. The Statin Response Examined by Genetic HAP Study, or STRENGTH, will look at Lipitor, Zocor, Pravachol, and Baycol.
At the end of the study, which will take about a year, Genaissance of New Haven, Conn., said it would have HAP markers that could eventually be used to help physicians determine which drug to prescribe to which patient.
"Today, physicians find that many of their patients don't respond optimally to their prescriptions and side effects can't be predicted," Kenneth Kashkin, chief medical officer at Genaissance Pharmaceuticals, said in a statement.
"We believe that the STRENGTH study will lead the way in replacing trial and error medicine with genomically-guided treatment decisions so that the right drug at the right dose reaches the patient,” he said.
Recently, DNAPrint Genomics, which is also trying to advance personalized medicine by studying patients’ responses to drugs, announced that it, too, would focus on researching the impact of statins on users.